SCHEMBL9225409

SCHEMBL9225409

CCC(C)CC(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
NPC1 O15118 2/20 0.56
L3MBTL1 Q9Y468 4/20 0.54
MAPT P10636 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
ALDH1A1 P00352 3/20 0.54
HPGD P15428 2/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 2/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
CES1 P23141 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12158744 1.00 TSHR (0.57) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL11530697 0.89 MAPT (0.62) KMT2AMEN1NPC1L3MBTL1MAPT
SCHEMBL963849 0.85 TSHR (0.53) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL14006544 0.84 TSHR (0.57) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL96580 0.84 TSHR (0.57) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL96579 0.84 TSHR (0.57) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL28751184 0.84 MAPT (0.47) KMT2AMEN1NPC1MAPTALDH1A1
SCHEMBL8845817 0.82 TSHR (0.55) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL4770344 0.82 GSK3B (0.55) TSHRKMT2AMEN1NPC1L3MBTL1
SCHEMBL11650548 0.82 ALDH1A1 (0.55) TSHRKMT2AMEN1NPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4516118-A2 USE OF AMBOCENIDE® FOR REINFORCING A LILY OF THE VALLEY NOTE Symrise AG (DE) 2025-03-05 EP claimed
EP-4516118-A2 USE OF AMBOCENIDE® FOR REINFORCING A LILY OF THE VALLEY NOTE Symrise AG (DE) 2025-03-05 EP disclosed
EP-2735581-B1 COMPOSITION AND POLYMER ASAHI CHEMICAL IND (JP) 2021-07-14 EP disclosed
EP-3665163-A1 USE OF AMBROCENIDE ® FOR INTENSIFYING A LILY OF THE VALLEY SCENT Symrise AG (DE) 2020-06-17 EP disclosed
US-10336893-B2 Process for preparing a modified ethylene-based polymer using a hydrocarbon initiator DOW GLOBAL TECHNOLOGIES LLC (US) 2019-07-02 US disclosed
CN-105754099-B Composition and polymer 旭化成株式会社 2018-09-18 CN disclosed
US-20170362419-A1 Process for Preparing a Modified Ethylene-Based Polymer Using a Hydrocarbon Initiator DOW GLOBAL TECHNOLOGIES LLC 2017-12-21 US disclosed
WO-2017174827-A1 USE OF AMBROCENIDE ® FOR INTENSIFYING A LILY OF THE VALLEY SCENT SYMRISE AG (DE) 2017-10-12 WO disclosed
US-9738757-B2 Composition and polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2017-08-22 US disclosed
US-20160222168-A1 Composition and Polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-08-04 US disclosed
EP-2735581-A1 COMPOSITION AND POLYMER Asahi Kasei Chemicals Corporation (JP) 2014-05-28 EP disclosed
US-20140121293-A1 Composition and Polymer ASAHI KASEI CHEMICALS CORPORATION (JP) 2014-05-01 US disclosed
CN-103502315-A Composition and polymer ASAHI KASEI CHEMICALS CORP 2014-01-08 CN disclosed
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS INC. (US) 2011-12-29 US disclosed
US-20110233653-A1 NON-VOLATILE SEMICONDUCTOR DEVICES AND METHODS OF MANUFACTURING NON-VOLATILE SEMICONDUCTOR DEVICES LEE HAK-SUN 2011-09-29 US disclosed
US-7594520-B2 Method of making a dual filter KING TECHNOLOGY (US) 2009-09-29 US disclosed
EP-0282895-B1 2-oxa-isocephem compounds, compositions containing same and processes for preparing same OTSUKA PHARMA CO LTD (JP) 1995-06-07 EP disclosed
US-5037976-A Antimicrobial Agent OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-08-06 US disclosed
US-4898859-A 2-Oxa-isocephem compounds and compositions containing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-02-06 US disclosed
EP-0282895-A2 2-oxa-isocephem compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 TSHR 302/4885KMT2A 1331/4885MEN1 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.